We're available 24/7. Call us anytime. (888) 552-6760
(888) 552-6760 SCHEDULE AN APPOINTMENT

Jana Portnow,

Medical Oncologist

Biography photo
Location
Duarte Comprehensive Cancer Center
1500 East Duarte Road
Duarte, CA 91010
Specialties
Medical Oncology
Education
Medical school:
Board Certifications

  • 2012, Recertified, American Board of Internal Medicine, Medical Oncology

  • 2001, Board Certified, American Board of Internal Medicine, Medical Oncology

  • 1997, Board Certified, American Board of Internal Medicine

Degrees

  • 1994, M.D., University of Rochester School of Medicine, Rochester, NY

  • 1989, B.A., Psychology, Brown University, Providence, RI

Fellowship

  • 1999-2002, Medical Oncology Fellow, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD

  • 1998-1999, Neuro-Oncology Fellow, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD

Residency

  • 1997-1998, Chief Resident, Department of Internal Medicine, Temple University Hospital, Philadelphia, PA

  • 1994-1997, Resident, Internal Medicine, Temple University Hospital, Philadelphia, PA

Professional Experience

  • 2021-present, Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA

  • 2021-present, Co-Director, Brain Tumor Program, City of Hope, Duarte, CA

  • 2012-2021, Associate Director, Brain Tumor Program, City of Hope, Duarte, CA

  • 2004-present, Member, City of Hope Patient Rights and Organizational Ethics Committee

  • 2012-2021, Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA

  • 2010-2012, Chair, City of Hope Data and Safety Monitoring Board

  • 2010-2012, Member, Clinical Research Governance Board

  • 2008-2010, Associate Chair, City of Hope Data & Safety Monitoring Committee

Academic Appointments
  • Professor, Department of Medical Oncology & Therapeutics Research
  • Co-Director, Brain Tumor Program
About Me
Neuro-oncologist Jana Portnow, M.D. (her pronouns: she/her), professor of medical oncology and co-director of City of Hope’s Brain Tumor Program, is a physician-researcher who has expertise in early-phase development of leading-edge therapies for brain tumors and has designed and conducted numerous clinical trials.
 
She has obtained millions of dollars of research funding from the National Institutes of Health, including most recently as co-principal investigator of an NIH grant through which City of Hope became part of the National Cancer Institute’s newly-formed Glioblastoma Therapeutics Network, a consortium of academic brain tumor centers that collaborate on preclinical and clinical studies to find better treatments for gliomas. Dr. Portnow has reviewed grant applications as a member of the NIH Clinical Oncology Study Section. She currently serves as Vice Chair person of the National Comprehensive Cancer Network’s panel on Guidelines for the Treatment of CNS Cancers.
 
Her research cultivates innovations against brain cancer, such as neural stem cells that act as a homing device to deliver therapies directly to tumors in the brain, including oncolytic viruses, which are genetically engineered to attack cancer. Dr. Portnow’s slate of clinical trials includes leading first-in-human studies of neural stem cells for aggressive gliomas and directly administered into the brain CAR T cell therapy, an immune treatment being investigated for its ability to fight cancer that spreads to the brain.
 
The grace and resilience of brain cancer patients are a daily source of inspiration for Dr. Portnow. Understanding that the disease they face affects the organ that is essential to our sense of self, she is determined to do everything she can to help these patients.
 
Dr. Portnow earned her medical degree from the University of Rochester, then pursued a residency in internal medicine at Temple University, where she was chief resident, and then completed fellowships in medical oncology and neuro-oncology at Johns Hopkins Medical Institute.
Patient ratings
Star ratings and comments are only available for medical, radiation and gynecologic oncologists. Gynecologic surgical offerings are not included at this time due to a different survey tool required to evaluate these services. CTCA uses a validated Press Ganey® survey, which captures patient experience feedback for the primary oncology services of chemotherapy and radiation therapy at our comprehensive care and research centers. Following industry best practice, star ratings and comments are only published for physicians with a minimum of 30 completed patient surveys.